Equities

Adocia SA

Adocia SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)8.76
  • Today's Change0.00 / 0.00%
  • Shares traded46.14k
  • 1 Year change+212.86%
  • Beta0.5880
Data delayed at least 15 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.

  • Revenue in EUR (TTM)5.73m
  • Net income in EUR-20.55m
  • Incorporated2006
  • Employees100.00
  • Location
    Adocia SA115 avenue LacassagneLYON 69003FranceFRA
  • Phone+33 472610610
  • Fax+33 472363967
  • Websitehttps://www.adocia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Maat Pharma SA2.31m-14.73m102.22m47.00--3.26--44.18-1.39-1.390.22012.700.0487.873.0053,813.95-30.58---38.13--76.19---636.60--4.14-60.840.2931--47.12---52.05------
Ose Immunotherapeutics SA2.23m-23.00m105.79m62.00--4.57--47.50-1.18-1.180.11661.060.0256--3.22---26.46-17.17-33.15-20.55-----1,032.87-94.71---97.810.6659---87.83-38.07-29.52---17.11--
Transgene SA7.63m-22.33m114.97m164.00------15.06-0.22-0.220.0759-------------24.81---29.79-----292.48-193.24---------23.681.5131.94--14.44--
Eurofins-Cerep SA46.17m9.21m116.01m233.0012.591.9310.362.511,826.411,826.419,160.0011,939.290.68141.666.04220,892.0013.6015.1916.0618.9485.5767.3019.9519.725.17112.420.000050.0014.4514.3017.0924.52----
Adocia SA5.73m-20.55m125.25m100.00------21.88-2.36-2.360.6532-1.900.1823--16.7955,048.08-65.43-25.65-341.43-37.22-----358.85-101.110.5924-2.782.81--692.73-10.0869.67---40.08--
DBV Technologies SA4.87m-93.97m128.82m88.00--0.8428--26.46-0.9973-0.99730.05171.580.0209--0.373870,562.52-40.35-64.67-46.22-80.94--91.59-1,929.97-1,345.10----0.0128---15.14-18.452.08---38.41--
AB Science SA777.00k-16.89m129.21m89.00------166.29-0.3561-0.35610.0164-0.38790.02840.3942.507,471.15-61.64-70.81-237.22-316.6388.1691.37-2,173.10-1,225.491.41--135.44---40.39-11.245.86--5.07--
Eurobio Scientific SA128.01m7.91m165.01m304.0021.321.046.771.290.75520.755211.9115.450.48563.754.48948,222.303.0021.703.5328.7945.2850.596.1825.062.704.110.37990.00-17.3829.03-58.81---6.24--
Genfit SA29.75m-34.17m166.45m154.00--2.23--5.59-0.6877-0.68770.59881.500.1381535.2516.86201,027.00-15.86-15.88-19.53-19.0292.8094.23-114.87-120.192.95-9.320.5030---68.9631.11-135.27------
Aelis Farma SA5.55m-5.57m171.69m22.00--9.98--30.92-0.4123-0.41230.41871.300.1405--1.36252,409.10-14.09-30.28-22.24-49.56-----100.29-168.222.41--0.1337---58.03---2,589.20------
Inventiva SA14.01m-80.08m173.02m117.00------12.35-1.90-1.900.3357-0.1820.1564--12.60124,008.90-89.37-40.86-136.45-49.44-----571.45-747.461.37-25.031.28--190.3920.48-9.35--5.56--
Innate Pharma SA51.90m-7.57m176.68m191.00--3.39--3.40-0.0843-0.08430.6170.64370.2648--1.77---3.86-8.83-4.87-12.1165.19---14.59-55.55----0.6408--4.68-8.2786.94--10.50--
Cellectis SA22.63m-54.96m178.52m----1.96--7.89-1.05-1.540.43911.270.0998--40.86---27.15-21.38-34.66-26.37---61.60-272.10-268.89---4.960.5559---33.35-5.27-5.77---14.21--
Data as of Mar 28 2024. Currency figures normalised to Adocia SA's reporting currency: Euro EUR

Institutional shareholders

0.60%Per cent of shares held by top holders
HolderShares% Held
NOVACAP Asset Management SAas of 31 Mar 202042.48k0.30%
Uzes Gestion SAas of 23 Feb 202430.00k0.21%
CGM � Azimut Monaco SAas of 31 Jan 202411.00k0.08%
Gestys SAas of 26 Jan 20241.10k0.01%
Iris Finance SAas of 31 Dec 20180.000.00%
More ▼
Data from 31 Dec 2018 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.